莫沙必利

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462255663
| IUPAC_name = (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide
| image = Mosapride.svg
| width = 180
| image2 = 3D Mosapride.png

| tradename =
| Drugs.com =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration = 口服

| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

| CAS_number_Ref =
| CAS_number = 112885-41-3
| ATC_prefix = none
| ATC_suffix =
| PubChem = 119584
| IUPHAR_ligand = 242
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 106780
| UNII_Ref =
| UNII = I8MFJ1C0BY
| KEGG_Ref =
| KEGG = D08236
| ChEMBL_Ref =
| ChEMBL = 60889

| C=21 | H=25 | Cl=1 | F=1 | N=3 | O=3
| molecular_weight = 421.893 g/mol
| smiles = Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
| InChI = 1/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
| InChIKey = YPELFRMCRYSPKZ-UHFFFAOYAO
| StdInChI_Ref =
| StdInChI = 1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
| StdInChIKey_Ref =
| StdInChIKey = YPELFRMCRYSPKZ-UHFFFAOYSA-N
| synonyms =
}}

莫沙必利（INN：mosapride）属于一种胃肠动力药，是选择性 5-HT4受体激动剂，其主要代谢产物 M1（des-p-fluorobenzyl mosapride）还具有 5HT3受体的竞争性拮抗作用，可加速人体整个胃肠道的排空。

莫沙必利用来治疗胃炎、胃食管反流病、功能性消化不良和肠易激综合征，也做為止吐劑，較不會誘發椎體外症候群。枸缘酸盐形式的莫沙必利，由大日本住友制药在1998年以加斯清为商品名上市销售。

參見
*蕈毒鹼拮抗劑(Muscarinic antagonist、蕈毒鹼性受體拮抗劑)

引用